Name: Latest research reports of Ajanta Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 1
Author: BOB Capital Markets Ltd.

Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Mid-range Performer

2883.2000 -14.10 (-0.49%)

NSE Apr 15, 2026 15:31 PM

Volume: 81,682

Ajanta Pharma Ltd.

11 Dec 2024

2883.20

-0.49%

Ajanta Pharma (SELL): No incremental triggers; valuation expensive

Sell: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

At our virtual conference AJP said it is not looking to venture into newer therapies in India in the next 1-2 years due to hefty valuations

Number of FII/FPI investors increased from 316 to 343 in Mar 2026 qtr.